Information sur le laboratoire
Sasha Bernatsky (M.D./Ph.D.)
Scientifique séniorCentre de recherche évaluative en santé
Département de médecine (McGill)
Profil de recherche
Mots-clés
Pharmacoépidémiologie • Lupus érythémateux disséminé • Maladie rhumatismale • Innocuité et efficacité des médicaments • Pollution atmosphériqueIntérêts de recherche
Mes recherches portent principalement sur les conséquences des maladies rhumatismales, la pharmacoépidémiologie et les effets de la pollution atmosphérique sur la santé.Membre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Lee, J. J. Y., Bernatsky, S., Benchimol, E. I., Kwong, J. C., Li, Q., Yeung, R. S. M. & Widdifield, J. (2025). Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: A population-based study. Paediatrics & child health, vol. 30, p. 305-311.
- Shapiro, J. R., Choi, F., Xu, A., Duong, T. T., Gingras, A.-C., Colwill, K., Bernatsky, S., Benseler, S. M., Yeung, R. S. & SUCCEED KIDS Team (2025). Immunogenicity of COVID-19 booster vaccines in children receiving immunosuppressive medications. Pediatric research.
- Birck, M. G., Boivin, J., Yan, L., Carrier, N., Moura, C. S., Maksymowych, W. P., Boire, G., Choquette, D., Lukusa, L., Mallinson, M., Wilhelm, L., Neville, A. & Bernatsky, S. (2025). Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis. Arthritis research & therapy, vol. 27, p. 150.
- Lee, J.-E., Mendel, A., Malhamé, I., Barber, M. R. W., Clarke, A. E., Fortin, P. R., Hanly, J. G., Legge, A., Peschken, C., Laskin, C. A., Touma, Z., Urowitz, M. B., Bernatsky, S. & Vinet, É. (2025). An educational tool to improve PREeclamPsia knowledge and Aspirin adheRence in lupus prEgnancies: the PREPARE trial. Rheumatology (Oxford, England).
- Flatman, L. K., Bernatsky, S., Bérard, A. & Vinet, É. (2025). Patterns of Use and Discontinuation for Tumour Necrosis Factor Inhibitors in Pregnant Women: Insights from a Real-World Sample. The Journal of rheumatology.
- Geslin, M., Vachon, J., Zhao, N., Sidi, E. A. L., Jean, S., Smargiassi, A. & Bernatsky, S. (2025). Systemic autoimmune rheumatic disease risk is associated with long-term exposure to fine particulate matter. Arthritis & rheumatology (Hoboken, N.J.).
- Nguyen, N., Bernatsky, S., Colmegna, I., Berger, C., Carrier, N., Allard-Chamard, H., Liang, P., Roux, S., Boire, G. & Hudson, M. (2025). Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Using an Extended Set of Clinical Variables: An Unmet Need. International journal of rheumatic diseases, vol. 28, p. e70281.
- Zhao, N., Al-Aly, Z., van Donkelaar, A., Martin, R. V., Assayag, D., Pineau, C. A. & Bernatsky, S. (2025). Fine particulate matter and interstitial lung disease in systemic autoimmune rheumatic diseases. The European respiratory journal, vol. 65.
- Tan, J., Bernatsky, S., Lee, J. L. F., Fortin, P. R., Dayam, R. M., Gingras, A.-C., Colmegna, I., Bowdish, D. M. E., Berger, C., Chan, D., Larché, M. J., Richards, D. P., Gonzalez Arreola, L., Hitchon, C. A., Lalonde, N. & Aviña-Zubieta, J. A. (2025). COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study. Vaccines, vol. 13.
- Krustev, E., Fritzler, M. J., Bernatsky, S., St Pierre, Y., Sciore, P. J., Vinet, E., Pineau, C. A., Mendel, A., Kalache, F., Grenier, L.-P., Cotton, T., Niaki, O. Z. & Choi, M. Y. (2025). Anti-myxovirus resistance protein 1: a novel biomarker for autoimmune myositis and interstitial lung disease in systemic lupus erythematosus. Annals of the rheumatic diseases, vol. 84, p. 881-882.
Voir aussi
